

PRESS RELEASE

29 December 2021 08:45:00 CET

Senzime Scientific and Clinical Advisory Board forums

News: Uppsala, on December 29, 2021. Senzime reports from their work with Advisory Board Forums gathering global experts in the field of anesthesiology for innovative business intelligence and strategic insights.

Scientific and clinical Advisory Boards (SABs/CABs) are a very effective and impactful way to engage with key customer executives. During these discussions we can address mutual challenges or opportunities, review industry trends as well as gather insight and feedback into our current and planned products making sure they answer the needs of clinicians and hospitals.

Our Advisory community includes Professors, Clinicians and Nurses certified and recognized for their unique capabilities and acumen as well as being scientific experts in their areas. There are currently three active board forums, two Scientific Advisory Boards (US & ROW) and one Clinical Advisory Board (Global). Visit our [website](#) for more information.

Pia Renaudin, CEO of Senzime, says: *“Understanding the need of our customers and how best to serve them is a key factor to our success and our mutual interest in working for patient safety. We strive to deliver cutting-edge technology facilitating the important work done by Anesthesia practitioners around the world.”*

Senzime was founded in Uppsala in 1999 and the company's shares are traded on Nasdaq Stockholm main market.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

Senzime Scientific and Clinical Advisory Board forums